Memory Aid by Intranasal Insulin in Diabetes (MemAID)
Status:
Completed
Trial end date:
2020-05-31
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to find the long-term effects of daily administration of 40
IU of intranasal insulin (INI) as compared to placebo (sterile saline) on cognition and
memory in people with type 2 diabetes mellitus (DM), and non-diabetic controls over 24 weeks
with a follow-up period for 24 weeks. Four groups will be tested: DM group treated with INI;
DM group treated with placebo; control group treated with INI and the control group treated
with placebo. The INI or placebo will be delivered into the nose. The investigators are
interested to see whether INI can improve memory and cognition and blood flow in the brain in
the type 2 DM group as compared to placebo and to the non-diabetic group over a long-term
period.
Phase:
Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
Medtronic National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Novo Nordisk A/S